Candel Therapeutics, Inc. CADL Treasury Stock
Treasury Stock at other companies
Other financials
Where this comes from
Reported directly by Candel Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:TreasuryStockValue.
The official record: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Candel Therapeutics, Inc.'s treasury stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Candel Therapeutics, Inc.'s treasury stock?
- Candel Therapeutics, Inc. (CADL) reported treasury stock of $448K in Q1 2026.
- How has Candel Therapeutics, Inc.'s treasury stock changed year-over-year?
- Candel Therapeutics, Inc.'s treasury stock decreased by 0.0% year-over-year, from $448K to $448K.
- What is the long-term trend for Candel Therapeutics, Inc.'s treasury stock?
- Over 3 years (2022 to 2025), Candel Therapeutics, Inc.'s treasury stock has grown at a 0.0% compound annual growth rate (CAGR), from $448K to $448K.
- What does treasury stock mean?
- Shares repurchased by the company and held in treasury, reducing equity. Recorded at cost and presented as a negative equity component.